Service offerings will include clinical and commercial lot release programmes, viral clearance testing, and virus and molecular-based safety detection services
WuXi PharmaTech, a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the US, has completed the construction of a new biologics biosafety testing facility in Suzhou, China.
The facility consists of 38,000ft2 of laboratories and support areas in a building adjacent to the company's GLP preclinical drug safety facility. Operations will begin after validations are completed this summer. Service offerings will include clinical and commercial lot release programmes, viral clearance testing, and virus and molecular-based safety detection services for Chinese and multinational customers.
The new services will expand WuXi's already broad, integrated platform of biologics services. In the United States, WuXi offers biosafety testing services such as viral clearance validation and lot release and stability testing. In China, the company's services include novel monoclonal antibody discovery, discovery biology, drug screening, cell-line engineering and construction, toxicology, bioanalytical services, assay development, formulation, process development, and cGMP drug-substance and drug-product manufacturing for clinical trials.
'WuXi's expanding capabilities help our customers advance their biologic product candidates through development more quickly and cost-effectively,' said Dr Ge Li, Chairman and CEO of WuXi PharmaTech.